Targeting APOE4

E-Scape Bio Inc. is the only company with a disclosed program targeting APOE4, a long-known risk marker for Alzheimer’s disease. By changing the molecule’s structure to resemble a non-toxic variant of apolipoprotein E, the company’s allosteric modulators aim to convert carriers of the risk allele to a normal phenotype.

The biotech was founded to identify subpopulations in CNS indications defined by genetic features that might be targetable...